研究者詳細 - 寺井　崇二

論文 - 寺井　崇二

分割表示 1,104 件中 621 - 640 件目／全件表示 >>

Diagnosis and management of fibromuscular dysplasia and segmental arterial mediolysis in gastroenterology field: A mini-review. 査読国際誌

Ko M, Kamimura K, Ogawa K, Tominaga K, Sakamaki A, Kamimura H, Abe S, Mizuno K, Terai S

World journal of gastroenterology 24 ( 32 ) 3637 - 3649 2018年8月

Potential role of extracellular vesicle-mediated antigen presentation in Helicobacter pylori hypersensitivity during eradication therapy. 査読国際誌

Takamasa Ito, Takashi Shiromizu, Shunsuke Ohnishi, Shotaro Suzuki, Katsuhiro Mabe, Akito Hasegawa, Hideyuki Ujiie, Yasuyuki Fujita, Yuichi Sato, Shuji Terai, Mototsugu Kato, Masahiro Asaka, Takeshi Tomonaga, Hiroshi Shimizu, Riichiro Abe

The Journal of allergy and clinical immunology 142 ( 2 ) 672 - 676 2018年8月

Gastric Cavernous Hemangioma Resected by Endoscopic Submucosal Dissection. 査読

Watanabe Y, Takahashi K, Yokoyama J, Terai S

Internal medicine (Tokyo, Japan) 57 ( 15 ) 2269 - 2270 2018年8月

The Value of <sup>18</sup>F-FDG PET in the Diagnosis of Intertrabecular Vertebral Metastasis in a Small Cell Lung Cancer Patient with a High Serum CEA Level. 査読

Morita S, Suda T, Oda C, Kobayashi M, Hoshi T, Kanefuji T, Yagi K, Hasegawa G, Terai S

Internal medicine (Tokyo, Japan) 58 ( 3 ) 415 - 418 2018年8月

Successful treatment of aortic dissection during sorafenib therapy for hepatocellular carcinoma. 査読国際誌

Tsuchiya A, Ogawa M, Watanabe Y, Kimura N, Hayashi K, Suda T, Terai S

Clinical case reports 6 ( 8 ) 1643 - 1644 2018年8月

Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies. 査読国際誌

Takamasa Kobayashi, Hirokazu Kawai, Oki Nakano, Satoshi Abe, Hiroteru Kamimura, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Satoshi Yamagiwa, Shuji Terai

BMC cancer 18 ( 1 ) 756 - 756 2018年7月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: The impact of sarcopenia on the prognosis of patients with hepatocellular carcinoma (HCC) who receive transcatheter intra-arterial therapies, including transcatheter arterial chemoembolization and transcatheter arterial infusion chemotherapy, remains unclear. We investigated the prognostic value of skeletal muscle loss (SML) stratified by cutoffs for sarcopenia and rate of change in skeletal muscle mass over 6 months. METHODS: We retrospectively evaluated 102 patients with HCC treated with transcatheter intra-arterial therapies between 2005 and 2015. Computed tomography images of the third lumbar vertebra (L3) were analyzed to obtain the skeletal muscle area normalized for the height squared, defined as the skeletal muscle index at L3 (L3 SMI), before and 6 months after treatment. Low or high SMI was defined using cutoff values of 42 cm2/m2 in men and 38 cm2/m2 in women. The rate of change in skeletal muscle mass (ΔL3 SMI) over 6 months was calculated. Overall survival (OS) was compared in groups classified by baseline L3 SMI and ΔL3 SMI; prognostic significance was assessed with univariate and multivariate analyses, using Cox proportional hazards models. RESULTS: OS did not differ significantly between groups with low (n = 31) and high (n = 71) SMI at baseline (P = 0.172), but OS was significantly poorer in patients with SML (n = 41), defined as ΔL3 SMI < - 4.6% over 6 months than in those without SML (n = 61, P = 0.018). On multivariate analysis, SML (hazard ratio [HR], 1.675; 95% confidence interval [CI], 1.031-2.721; P = 0.037), serum alpha-fetoprotein ≥20 ng/mL (HR, 2.550; 95% CI, 1.440-4.515; P = 0.001), and maximum tumor diameter ≥ 30 mm (HR, 1.925; 95% CI, 1.166-3.179; P = 0.010) were independent predictors of poor OS. Baseline L3 SMI was not significantly associated with OS (HR, 1.405; 95% CI, 0.861-2.293; P = 0.174). CONCLUSIONS: ΔL3 SMI was an independent prognostic factor in patients with HCC treated with transcatheter intra-arterial therapies. Further study is required to reveal whether prevention of skeletal muscle depletion might be a new therapeutic strategy to contribute to improved clinical outcomes in patients with HCC.

DOI： 10.1186/s12885-018-4673-2

PubMed

researchmap

Management decision based on lymphovascular involvement leads to favorable outcomes after endoscopic treatment of esophageal squamous cell carcinoma 査読

Kazuya Takahashi, Satoru Hashimoto, Ken-Ichi Mizuno, Takamasa Kobayashi, Kentaro Tominaga, Hiroki Sato, Junji Kohisa, Satoshi Ikarashi, Kazunao Hayashi, Manabu Takeuchi, Junji Yokoyama, Hirokazu Kawai, Yuichi Sato, Masaaki Kobayashi, Shuji Terai

Endoscopy 50 ( 7 ) 662 - 670 2018年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Georg Thieme Verlag

Background Esophageal squamous cell carcinoma (ESCC) invading the muscularis mucosae (MM) and submucosa up to 200μm (SM1) has a risk of metastasis. The aims of this study were to investigate the long-term outcome of endoscopic submucosal dissection (ESD) for MM/SM1 ESCC and to assess the management after ESD in our hospital. Methods This was a retrospective cohort study conducted at a single institution. Patients with MM or SM1 ESCC who were treated with ESD were included. Additional prophylactic therapy was added if lymphovascular involvement (LVI) was noted in the ESD specimens. Results A total of 102 patients were analyzed. The median length of follow-up was 71.5 months (range 9-144 months) and the median number of CTs was 6 (range 0-24). LVI was found in 21 patients (20.6%), and 12 patients underwent additional prophylactic therapy. The 5-year overall survival, disease-specific survival, and tumor-free survival rates were 84.1%, 97.5%, and 82.1%, respectively. A total of 26 patients died, but only 2 of them died from ESCC. The cumulative metastasis rate was 11.8%, and LVI was a significant predictor of metastasis (hazard ratio 5.42, 95% confidence interval 1.39-21.18
P =0.02). There were no differences between patients with MM ESCC and those with SM1 ESCC. Conclusions The long-term outcome after ESD for MM/SM1 ESCC was favorable with additional prophylactic therapy and strict adherence to follow-up.These results indicate that our management decision based on LVI is a valid approach and that ESD can be offered as a therapeutic option to MM/SM1 ESCCs.

DOI： 10.1055/s-0043-124433

Scopus

PubMed

researchmap

A case of inferior vena cava thrombosis caused by compression due to growing giant liver cyst. 査読

Kimura N, Tsuchiya A, Ogawa M, Watanabe Y, Hayashi K, Yokoyama J, Umezu H, Terai S

Clinical journal of gastroenterology 12 ( 1 ) 71 - 75 2018年7月

Anti-Programmed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis. 査読国際誌

Ogawa K, Kamimura K, Terai S

Hepatology (Baltimore, Md.) 69 ( 2 ) 914 - 916 2018年7月

Renal Impairment in Chronic Hepatitis B: A Review. 査読国際誌

Hiroteru Kamimura, Toru Setsu, Naruhiro Kimura, Takeshi Yokoo, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Satoshi Yamagiwa, Shuji Terai

Diseases (Basel, Switzerland) 6 ( 2 ) 2018年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

The liver plays a key role in the metabolism of proteins. Liver dysfunction affects many organs because it communicates with the spleen and all digestive organs through the portal vein. Additionally, the kidney is an organ that is closely related to the liver and is involved in liver diseases. Glomerulonephritis is an important extrahepatic manifestation of chronic hepatitis B virus (HBV) infection. Nucleos(t)ide analog (NA) therapy effectively suppresses HBV replication by inhibiting HBV polymerase, thus decreasing the levels of serum HBV-DNA and delaying the progression of cirrhosis. Although NA therapy is recommended for all patients with chronic HBV infection, regardless of the level of renal dysfunction, there is limited information on NA use in patients with chronic kidney disease. In addition, in patients with end-stage liver cirrhosis, hepatorenal syndrome can be fatal. Hence, we should take into account the stage of impaired renal function in patients with cirrhosis. The aims of this article are to review the epidemiology, clinical presentation, treatment, and prevention of HBV-associated nephropathy.

DOI： 10.3390/diseases6020052

PubMed

researchmap

Eosinophilic Esophageal Myositis (EoEM) Causes Jackhammer Esophagus, Rarely Posing a Problem in the Differential Diagnosis of Eosinophilic Esophagitis 査読

Hiroki Sato, Shuji Terai

American Journal of Gastroenterology 113 ( 8 ) 1 - 2 2018年6月

Reply to the letter to the editor: Lymph node metastasis of adenocarcinoma and different definitions of sm1 cancer in the esophagus 査読

Ryu Ishihara, Tsuneo Oyama, Seiichiro Abe, Hiroaki Takahashi, Hiroyuki Ono, Junko Fujisaki, Mitsuru Kaise, Kenichi Goda, Kenro Kawada, Tomoyuki Koike, Manabu Takeuchi, Rie Matsuda, Dai Hirasawa, Masayoshi Yamada, Junichi Kodaira, Masaki Tanaka, Masami Omae, Akira Matsui, Takashi Kanesaka, Akiko Takahashi, Shinichi Hirooka, Masahiro Saito, Yosuke Tsuji, Yuki Maeda, Hiroharu Yamashita, Ichiro Oda, Yasuhiko Tomita, Takashi Matsunaga, Shuji Terai, Soji Ozawa, Tatsuyuki Kawano, Yasuyuki Seto

Journal of Gastroenterology 53 ( 6 ) 804 - 805 2018年6月

Nationwide survey for acute liver failure and late-onset hepatic failure in Japan 査読

Masamitsu Nakao, Nobuaki Nakayama, Yoshihito Uchida, Tomoaki Tomiya, Akio Ido, Isao Sakaida, Osamu Yokosuka, Yasuhiro Takikawa, Kazuaki Inoue, Takuya Genda, Masahito Shimizu, Shuji Terai, Hirohito Tsubouchi, Hajime Takikawa, Satoshi Mochida

Journal of Gastroenterology 53 ( 6 ) 752 - 769 2018年6月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Tokyo

Background: A nationwide survey was performed to clarify the recent status of acute liver failure (ALF) and late-onset hepatic failure (LOHF) in Japan. Methods: Two-step surveys for patients with ALF and LOHF meeting the Japanese diagnostic criteria were performed annually in 782 hospitals. The clinical features of the patients were then compared to those reported in previous surveys. Results: In total, 1554 and 49 patients with ALF and LOHF, respectively, who were seen between 2010 and 2015 were enrolled. The subjects were classified into 1280 patients with hepatitis (642 non-comatose and 638 comatose) and 323 patients without hepatitis (190 non-comatose and 133 comatose). Compared with patients seen between 1998 and 2009, an older patient age and a higher percentage of underlying extrahepatic disease were observed. Although hepatitis virus infection was the most frequent etiology, the percentage of patients with this etiology had decreased, compared with previous cohorts, while the percentages of patients with drug-induced liver injuries, autoimmune hepatitis, and an indeterminate etiology had increased. Liver transplantation was performed in 170 patients (10.6%), whereas artificial liver support with plasmapheresis and/or hemodiafiltration were performed for most of the comatose patients. The outcomes of comatose patients were unfavorable, similar to previous surveys, especially the outcomes of hepatitis B virus carriers, including those with de novo hepatitis B (survival rate of 5.4% without liver transplantation). Conclusion: Although the clinical features, including the etiologies, of patients with ALF and LOHF have changed, the outcomes of patients have not improved in recent years.

DOI： 10.1007/s00535-017-1394-2

Scopus

PubMed

researchmap

IS ENDOSCOPIC SUBMUCOSAL DISSECTION VALUABLE FOR ELDERLY PATIENTS WITH SUPERFICIAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA? 査読

Hashimoto Satoru, Mizuno Kenichi, Takahashi Kazuya, Sato Hiroki, Tominaga Kentaro, Kohisa Junji, Ikarashi Satoshi, Hayashi Kazunao, Yokoyama Junji, Terai Shuji

GASTROINTESTINAL ENDOSCOPY 87 ( 6 ) AB287 - AB287 2018年6月

Persistent reduction of mucosal-associated invariant T cells in primary biliary cholangitis. 査読国際誌

Toru Setsu, Satoshi Yamagiwa, Kentaro Tominaga, Naruhiro Kimura, Hiroki Honda, Hiroteru Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Shuji Terai

Journal of gastroenterology and hepatology 33 ( 6 ) 1286 - 1294 2018年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND AND AIM: Mucosal-associated invariant T (MAIT) cells constitute a novel subset of innate-like T lymphocytes characterized by a semi-invariant T-cell receptor repertoire capable of recognizing bacterial products. Considering the abundance of MAIT cells in the liver and the possible association between bacterial infections and primary biliary cholangitis (PBC), we aimed to analyze the involvement of MAIT cells in the immunopathogenesis of PBC. METHODS: Peripheral blood and liver biopsy specimens were collected from 25 patients with PBC and 19 patients with chronic viral hepatitis. Surgically removed liver tissues distant from tumors in patients with metastatic liver tumors were used as controls. Mononuclear cells were separated using Ficoll gradient, and the expression of various markers was investigated by flow cytometry. Cytokine production was investigated using blood MAIT cells after stimulation by anti-CD3/CD28-coupled beads with/without interleukin-7 (IL-7). RESULTS: Mucosal-associated invariant T cells were significantly reduced in both the blood and liver of PBC patients compared with those in controls. MAIT cells in the blood of PBC patients expressed significantly lower levels of activation markers and IL-7 receptor. Moreover, MAIT cells in the blood of PBC patients showed impaired production of cytokines, especially tumor necrosis factor alpha, after in vitro stimulation with IL-7. Interestingly, even after biochemical responses were achieved by ursodeoxycholic acid treatment, the frequencies of MAIT cells did not fully recover to normal levels. CONCLUSIONS: These findings suggested that MAIT cells were activated, exhausted, and persistently depleted in PBC patients even after ursodeoxycholic acid treatment, possibly as a consequence of persistent liver inflammation.

DOI： 10.1111/jgh.14076

PubMed

researchmap

ENDOSCOPIC MANAGEMENT OF UNRESECTABLE MALIGNANT HILAR STRICTURES USING THREADED INSIDE STENTS VERSUS METALLIC STENTS 査読

Hayashi Kazunao, Ikarashi Satoshi, Kohisa Junji, Takahashi Kazuya, Tominaga Kentaro, Mizuno Ken-ichi, Hashimoto Satoru, Yokoyama Junji, Yamagiwa Satoshi, Terai Shuji

GASTROINTESTINAL ENDOSCOPY 87 ( 6 ) AB208 - AB208 2018年6月

IS ENDOSCOPIC SUBMUCOSAL DISSECTION A FEASIBLE TREATMENT FOR ESOPHAGOGASTRIC JUNCTION CANCER? 査読

Takahashi Kazuya, Hashimoto Satoru, Mizuno Kenichi, Sato Hiroki, Tominaga Kentaro, Kohisa Junji, Ikarashi Satoshi, Hayashi Kazunao, Yokoyama Junji, Terai Shuji

GASTROINTESTINAL ENDOSCOPY 87 ( 6 ) AB396 - AB397 2018年6月

SAFETY AND EFFICACY OF PROPOFOL-BASED SEDATION FOR BALLOON ENTEROSCOPE-ASSISTED ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN ELDERLY PATIENTS 査読

Kohisa Junji, Ikarashi Satoshi, Hayashi Kazunao, Takahashi Kazuya, Tominaga Kentaro, Mizuno Kenichi, Hashimoto Satoru, Yokoyama Junji, Yamagiwa Satoshi, Terai Shuji

GASTROINTESTINAL ENDOSCOPY 87 ( 6 ) AB229 - AB229 2018年6月

フランシーン形状針を用いたEUS-FNAの有用性についての検討

河久順志, 林和直, 寺井崇二

ENDOSCOPIC FORUM for digestive disease 34 ( 1 ) 73 - 73 2018年6月

How do you treat this diversion ileitis and pouchitis? 査読

Kentaro Tominaga, Atsunori Tsuchiya, Junji Yokoyama, Shuji Terai

Gut 2018年5月

　前のページ - 次のページ　

<寺井 崇二>

論文 - 寺井 崇二

<寺井　崇二>

論文 - 寺井　崇二